Navigation Links
Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
Date:1/14/2008

BRIDGEWATER, N.J. and CINCINNATI, Jan. 14 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were published this month in the January issue of the peer- reviewed journal Bone. In the non-inferiority study comparing risedronate 150 mg once monthly to risedronate 5 mg daily, increases in lumbar spine bone mineral density (BMD) at one year were similar for patients taking either the monthly or daily dosing regimens. All patients were supplemented with calcium and vitamin D.

In the study, BMD was measured at the lumbar spine, total hip, femoral neck, and femoral trochanter. There were no statistically significant differences in BMD increases between the risedronate 150 mg once monthly and the 5 mg daily dose groups at 12 months at all sites. In the study, the tolerability and safety profiles also were generally similar for the monthly and daily dosing regimens of risedronate.

"Our goal is to provide patients with convenient dosing options for risedronate," said Nora Zorich, M.D., Ph.D., Vice President, Global R&D, P&G Pharmaceuticals. "If this dose regimen is approved, there will be a once monthly dose option available to patients seeking less frequent dosing of risedronate."

About the Study

The MERIT-OP (Monthly Evaluation of Risedronate Trial in Osteoporosis) study is a 2-year, randomized, double-blind, active-control (5 mg daily risedronate) clinical trial which evaluated 1,292 postmenopausal women between 50 and 88 years old, mean age 64.9, from 47 clinical centers in 13 countries. The participants had osteoporosis, defined as a lumbar spine (LS) BMD T-score less than -2.5 or a LS BMD T-score less than -2.0 and at least one prevalent vertebral fracture. Patients were randomized to dosing regimens of either risedronate 150 mg monthly or risedronate 5 mg daily and received daily supplements of calcium
'/>"/>

SOURCE Procter & Gamble
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  Seventy-one percent of Americans believe the ... a serious public health and safety issue in ... survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse problem ... this very serious health situation facing our country," Rex ...
(Date:8/21/2014)...  Henry Schein, Inc. (NASDAQ: HSIC ), the ... office-based dental, animal health and medical practitioners, announced today that ... , September 4, 2014 – Baird 2014 Healthcare ... p.m. ET , September 8, 2014 – ... , NY at 1:25 p.m. ET Henry ...
(Date:8/21/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... and consideration payable in connection with its previously announced cash ... for (1) any and all of its 6.250% Senior Notes ... to a maximum amount of its 6.125% Senior Notes due ... due 2017 (collectively, the "Maximum Tender Offer Notes" and together ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3Henry Schein To Present At Two Investor Conferences In September 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6
(Date:8/22/2014)... (PRWEB) August 22, 2014 Key West ... care experts revealed their much anticipated study results of ... skin today and released an accompanying infographic on their ... in can have a major impact on the skin ... wrinkles and more. , When asked how they determined ...
(Date:8/22/2014)... (ESMO), the leading pan-European organisation representing medical oncology ... individuals receiving the Society,s esteemed annual awards. The ... Joensuu and Peter Boyle on the occasion of ... , Carsten Bokemeyer will receive the ESMO Award ... cancer discovery into real benefit at patient level. ...
(Date:8/22/2014)... provides insight on how the brain processes external input ... and sides of the body, in order to select ... in the journal Neuron , show that the ... of sensory information, with specialised functional roles for the ... input structure in the basal ganglia, and is typically ...
(Date:8/22/2014)... the leading pan-European organisation representing medical oncology professionals, ... receiving the Society,s esteemed annual awards. The awards ... and Peter Boyle on the occasion of the ... Carsten Bokemeyer will receive the ESMO Award for ... discovery into real benefit at patient level. 1 ...
(Date:8/22/2014)... News) -- The air in American cities is getting ... Thursday. Significant progress has been made in reducing ... decades, the agency said in a news release. ... reduction in mercury from human sources such as coal-fired ... 84 percent fall in lead, which harms brain development ...
Breaking Medicine News(10 mins):Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:The striatum acts as hub for multisensory integration 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... awe, not to mention a little fear or suspicion; it is ... hope to enter. Such an // approach can be dangerous if ... ,If the public is to have a say in developing guidelines ... clear sense of what science can and cannot be expected to ...
... people in the world after South Africa and now threats// ... to a World Economic Survey. ,The surveys message ... business due to AIDS in the next five years.", ... report some impact of the AIDS virus on ...
... checking the profits and safety of the drugs the ... monitor that only branded and quality medicines are sold ... Pharmaceutical Price Regulation Scheme [PPRS] is a voluntary organization ... and quality of the drugs every 5 years. It ...
... a disaster-planning guide to help the people who live ... hurricanes, tidal waves and cyclones. ,No matter where ... some sort of natural disaster such as a blizzard, ... are also possible. Both natural disasters and terrorist attacks ...
... increasing malfunction of heart devices, which they say were ... ,The Food and Drug Administration (FDA) released // ... manufacturers recently, which found that 4,225 defibrillators had failed ... in the previous 10 years, reports online edition of ...
... repair the damages in the heart from the use of stem ... to repair heart damage in sheep, reporting their results // in ... failure is a major cause of death in developed countries, occurring ... Before now, embryonic stem cells had been used to limit the ...
Cached Medicine News:Health News:Scientists Awarded Appropriately For Contribution Towards Medical Research 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Disaster Planning Guide From Harvard Health Publications 2Health News:Scientists Concerned Over Increasing Malfunction Of Heart Devices 2
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With tubular ...
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Medicine Products: